What is Bioventus's cash & equivalents?

Bioventus (BVS) reported cash & equivalents of $35.85M in Q1 2026.

How has Bioventus's cash & equivalents changed year-over-year?

Bioventus's cash & equivalents increased by 57.2% year-over-year, from $22.8M to $35.85M.

What is the long-term trend for Bioventus's cash & equivalents?

Over 5 years (2020 to 2025), Bioventus's cash & equivalents has grown at a -10.0% compound annual growth rate (CAGR), from $86.84M to $51.24M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Bioventus BVS Cash & Equivalents

Cash & Equivalents at other companies

StrykerSYK

$2.88B+24.1%

Zimmer Biomet HoldingsZBH

$424.2M-69.4%

MedtronicMDT

$1.95B-12.1%

SI-BONE, Inc.SIBN

$33.54M-18.6%

ArtivionAORT

$55.76M+47.9%

Globus MedicalGMED

$560.95M+21.6%

Other financials

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

See full

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bioventus's cash & equivalents?: Bioventus (BVS) reported cash & equivalents of $35.85M in Q1 2026.
How has Bioventus's cash & equivalents changed year-over-year?: Bioventus's cash & equivalents increased by 57.2% year-over-year, from $22.8M to $35.85M.
What is the long-term trend for Bioventus's cash & equivalents?: Over 5 years (2020 to 2025), Bioventus's cash & equivalents has grown at a -10.0% compound annual growth rate (CAGR), from $86.84M to $51.24M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.